newsfilter
← Latest News
GlobeNewswire·

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting with FDA for MASH Program Scheduled in Fourth Quarter Executive Leadership Strengthened with Appointments